{"brief_title": "Efficacy and Safety of Oral Bosentan in Pulmonary Fibrosis Associated With Scleroderma", "brief_summary": "Clinical and experimental studies suggest that bosentan could delay the progression of interstitial lung disease (ILD) associated with systemic sclerosis (SSc), a condition for which no established efficacious treatment is available. The present trial investigates a possible use of oral bosentan, which is currently approved for the treatment of symptoms of pulmonary arterial hypertension (PAH) WHO Class III and IV, to a new category of patients suffering from ILD associated with SSc.", "condition": "Scleroderma, Systemic", "intervention_type": "Drug", "intervention_name": "Bosentan", "criteria": "Main inclusion criteria: - Systemic Sclerosis diffuse or limited - Significant Interstitial Lung Disease on HRCTscan - DLco < 80% predicted - Dyspnea on exertion - Walk not limited by musculoskeletal reasons Main exclusion criteria: - Interstitial Lung Disease due to other conditions than SSc - End stage restrictive or obstructive lung disease - Severe cardiac or renal diseases - Significant pulmonary arterial hypertension - Smoker (> 5cig./day) - Treatment with immunosuppressive, antifibrotic drugs, high dose corticosteroids (within 4 weeks of randomization)", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00070590.xml"}